JP2016501221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501221A5 JP2016501221A5 JP2015545145A JP2015545145A JP2016501221A5 JP 2016501221 A5 JP2016501221 A5 JP 2016501221A5 JP 2015545145 A JP2015545145 A JP 2015545145A JP 2015545145 A JP2015545145 A JP 2015545145A JP 2016501221 A5 JP2016501221 A5 JP 2016501221A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- cdk4
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730661P | 2012-11-28 | 2012-11-28 | |
| US61/730,661 | 2012-11-28 | ||
| PCT/US2013/071659 WO2014085318A1 (en) | 2012-11-28 | 2013-11-25 | Combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018176231A Division JP2019031500A (ja) | 2012-11-28 | 2018-09-20 | 併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501221A JP2016501221A (ja) | 2016-01-18 |
| JP2016501221A5 true JP2016501221A5 (enExample) | 2017-01-12 |
Family
ID=49753505
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545145A Withdrawn JP2016501221A (ja) | 2012-11-28 | 2013-11-25 | 併用療法 |
| JP2018176231A Withdrawn JP2019031500A (ja) | 2012-11-28 | 2018-09-20 | 併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018176231A Withdrawn JP2019031500A (ja) | 2012-11-28 | 2018-09-20 | 併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9408847B2 (enExample) |
| EP (1) | EP2925365A1 (enExample) |
| JP (2) | JP2016501221A (enExample) |
| KR (1) | KR20150089053A (enExample) |
| CN (1) | CN104812414A (enExample) |
| AU (4) | AU2013352406A1 (enExample) |
| BR (1) | BR112015012197A8 (enExample) |
| CA (1) | CA2891938A1 (enExample) |
| HK (1) | HK1211475A1 (enExample) |
| MX (1) | MX2015006809A (enExample) |
| RU (1) | RU2015125307A (enExample) |
| WO (1) | WO2014085318A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY161237A (en) * | 2011-07-01 | 2017-04-14 | Novartis Ag | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer |
| US9527857B2 (en) | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| EP4035664A3 (en) | 2014-03-28 | 2022-11-30 | Duke University | Treating cancer using selective estrogen receptor modulators |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| CA2979215A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CN106336412A (zh) * | 2015-07-10 | 2017-01-18 | 南开大学 | 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
| EP3156406A1 (en) * | 2015-10-14 | 2017-04-19 | ratiopharm GmbH | Crystalline forms of ribociclib free base |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| RU2769527C2 (ru) * | 2016-06-22 | 2022-04-01 | Эллипсес Фарма Лтд | Способы лечения ar+ рака молочной железы |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
| MX2019010981A (es) * | 2017-03-16 | 2020-09-07 | Eisai R&D Man Co Ltd | Terapias de combinacion para el tratamiento de cancer de mama. |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN111214468B (zh) * | 2018-11-23 | 2021-02-05 | 苏州亚盛药业有限公司 | 新型药物组合物及其用途 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011240735B2 (en) * | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
-
2013
- 2013-11-25 KR KR1020157016810A patent/KR20150089053A/ko not_active Ceased
- 2013-11-25 MX MX2015006809A patent/MX2015006809A/es unknown
- 2013-11-25 EP EP13802807.1A patent/EP2925365A1/en not_active Withdrawn
- 2013-11-25 CN CN201380061379.0A patent/CN104812414A/zh active Pending
- 2013-11-25 US US14/646,206 patent/US9408847B2/en not_active Expired - Fee Related
- 2013-11-25 HK HK15112282.5A patent/HK1211475A1/xx unknown
- 2013-11-25 WO PCT/US2013/071659 patent/WO2014085318A1/en not_active Ceased
- 2013-11-25 JP JP2015545145A patent/JP2016501221A/ja not_active Withdrawn
- 2013-11-25 RU RU2015125307A patent/RU2015125307A/ru not_active Application Discontinuation
- 2013-11-25 CA CA2891938A patent/CA2891938A1/en not_active Abandoned
- 2013-11-25 BR BR112015012197A patent/BR112015012197A8/pt not_active IP Right Cessation
- 2013-11-25 AU AU2013352406A patent/AU2013352406A1/en not_active Abandoned
-
2016
- 2016-11-25 AU AU2016262781A patent/AU2016262781A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200323A patent/AU2018200323A1/en not_active Abandoned
- 2018-09-20 JP JP2018176231A patent/JP2019031500A/ja not_active Withdrawn
-
2019
- 2019-02-08 AU AU2019200881A patent/AU2019200881A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501221A5 (enExample) | ||
| RU2015125307A (ru) | Комбинированная терапия | |
| JP2016536286A5 (enExample) | ||
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2016533366A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| JP2015536964A5 (enExample) | ||
| EA202092671A1 (ru) | Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания | |
| JP2011102304A5 (enExample) | ||
| JP2017524735A5 (enExample) | ||
| CY1119227T1 (el) | Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock | |
| JP2013522326A5 (enExample) | ||
| MX2013012588A (es) | Inhibidores de cinasa. | |
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MX2017011635A (es) | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| JP2017517565A5 (enExample) | ||
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| JP2015502926A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| CN109689652A (zh) | 稠杂环类衍生物、其制备方法及其在医学上的应用 |